联合应用埃索美拉唑和瑞巴派特治疗活动期胃溃疡的疗效分析  

Efficacy of Combined Use of Esomeprazole and Rebamipide in the Treatment of Active Gastric Ulcer

作　　者：李青[1] 孙咏红[1] 

机构地区：[1]大连市友谊医院消化内科,辽宁大连116001

出　　处：《中国医药指南》2017年第7期117-118,共2页Guide of China Medicine

摘　　要：目的联合应用埃索美拉唑和瑞巴派特治疗活动期胃溃疡的疗效分析。方法选取在大连市友谊医院消化内科就诊的100例活动期胃溃疡的患者,就诊时间为2015年1月至2015年11月,按照治疗方法的不同分为试验组50例,采取埃索美拉唑和瑞巴派特治疗,对照组50例采取埃索美拉唑治疗,疗程均为4周,比较两组患者的临床疗效,以及镜下溃疡面的变化。结果 4周后,试验组各指标均优于对照组(P<0.05)。结论采用埃索美拉唑和瑞巴派特治疗活动期胃溃疡可有效改善患者胃黏膜、缩小溃疡面、改善临床症状,值得在临床推广。Objective Analysis of curative effect of the combination of esomeprazole and rebamipide in treatment of gastric ulcer. Methods In 100 cases of gastric ulcer in Dalian Friendship Hospital digestion Department of internal medicine in our hospital patients, visiting time is from January 2015 to November 2015, according to the different treatment methods are divided into experimental group 50 cases, taking esomeprazole and rebamipide treatment, 50 cases in the control group took esomeprazole treatment. The treatment lasted for 4 weeks. The clinical efficacy of two groups were compared, and the change in endoscopic ulcer. Results After 4 weeks, the test group was better than the control group（P〈0.05）. Conclusion The use of esomeprazole and rebamipide in treatment of gastric ulcer can effectively improve the patients of gastric mucosa, reduce the ulcer and improve clinical symptoms, worthy of promotion.

关 键 词：埃索美拉唑 瑞巴派特 治疗活动期胃溃疡 

分 类 号：R573.1[医药卫生—消化系统]